At Prestige Medical Group, our experienced medical providers create personalized peptide protocols tailored to your goals and conduct ongoing monitoring to ensure safety and effectiveness
Study 1 (NCT 00123253) This study re-randomized 207 HIV-infected patients with lipodystrophy who completed a 2 mg dose of EGRIFTA (1 mg/vial formulation) treatment in the Main Phase to receive either EGRIFTA (N=154) or placebo (N=50) for an additional 26-week duration (3:1 randomization ratio)
It has been our policy to report the actual amount of outlier payments as a percent of total spending in the claims being used to model the OPPS
The second method, involving radiofrequency, requires a few sessions before you see an improvement in your skins appearance
GAIN CONFIDENCE
Without writing a book and explaining every single trial in detail, Ill share the key takeaway points: Trials #1-4 demonstrated an excellent safety profile in which AOD-9604 was well-tolerated and safe, with next to no difference compared to a placebo Trial #5 saw patients taking the AOD-9604 peptide lose 2.8 kg on a dose of 1 mg, compared to the placebo group losing 0.8 kg over the same time period
